ESC Premium Access

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Presentation

About the speakers

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
31 presentations
0 follower

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)
7 presentations
1 follower

Professor Marc Pfeffer

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
23 presentations
0 follower

3 more presentations in this session

Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Speaker: Professor L. Ryden (Stockholm, SE)

Thumbnail

Results from the LEADER cardiovascular outcomes trial.

Speaker: Doctor M. Husain (Toronto, CA)

Thumbnail

Translating trials into practice – Clinical implications .

Speaker: Professor M. Pfeffer (Boston, US)

Thumbnail

Access the full session

GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

Speakers: Professor L. Ryden, Doctor M. Husain, Professor M. Pfeffer, Professor L. Ryden, Doctor M. Husain...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk